Adjunctive aripiprazole decreased metabolic side effects of clozapine treatment

Neuroendocrinology Letters

Volumn 29, Issue 4, 2008, Pages 435-437

  Masopust, Jiří ^a   Tůma, Ivan ^a   Libiger, Jan ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Aripiprazole; Clozapine; Metabolic side effects; Negative symptoms; Quality of life

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLONAZEPAM; CLOZAPINE; HALOPERIDOL; OLANZAPINE; VENLAFAXINE;

ADULT; ARTICLE; AUDITORY HALLUCINATION; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DELUSIONAL DISORDER; DEPRESSION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MENTAL DISEASE; METABOLIC DISORDER; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 54349121537     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Abu-Tair F, Kopitz J, Bergmann N. Clozapine augmented with aripiprazole in 5 patients with schizophrenia. J Clin Psychopharmacol 2006; 26: 669-671.
2. Cassano GB, Fagiolini A, Lattanzi L, Monteleone P, Niolu C, Sacchetti E, Siracusano A, Vita A. Aripiprazole in the treatment of schizophrenia. A consensus report produced by schizophrenia experts in Italy. Clin Drug Invest 2007; 27: 1-13.
3. Clarke LA, Lindenmayer JP, Kaushik S. Clozapine augmentation with aripirazole for negative symptoms (letter). J Clin Psychiatry 2006; 67: 675-676.
4. De Hert M, Hanssen L, van Winkel R, Wampers M, Van Eyck D, Scheen A, Peuskens J. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull 2007; 33:823-30.
5. Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, Freudenreich O, Evins AE, Cather C, Goff DC. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005; 66: 1116-1121.
6. Henderson DC, Kukel L, Nguyen DD, Borba CP, Daley TB, Loise PM, Freudenreich O, Cather C, Evins AE, Goff DC. An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006; 113: 142-147.
7. Karunakaran K, Tungaraza TE, Harborne G. Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia? J Psychopharmacol 2007; 21: 453-456.
8. Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, Roukas DK. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. European Psychiatry 2005; 20: 409-415.
9. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, teinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth DL. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003; 28: 519-526.
10. Mitsonis CI, Dimopoulos NP, Mitropoulos PA, Kararisou EG, Katsa AN, Tsakiris FE, Katsanou MN. Aripiprazole augmentation in the managment of residual symptoms in clozapine - treated outpatients with chronic schizophrenia: An open-label pilot study. Prog Neuropsychopharamacol Biol Psychiatry 2007; 31: 373-377.
11. Mohr P. Quality of life in the long-term treatment and the role of second-generation antipsychotics. Neuroendocrinol Lett 2007; 28 (Suppl 1): 117-133.
12. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patiens with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003; 64: 1048-1056.
13. Remington G, Saha A, Chong SA, Shammi CH. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005; 19: 843-872.
14. Rocha FL, Hara C. Benefits of combining aripiprazole to clozapine: Three case reports Prog Neuropsycholpharamacol Biol Psychiatry 2006; 30: 1167-1169.
15. Shapiro DA, Renock S, Arrington E, Chlodo LA, Liu L-X, Sibley DR, Roth BL, Mallman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28: 1400-1411.
16. Spurling RD, Lamberti JS, Olsen D, Tu X, Tang W. Changes in metabolic parameters with switching ti aripiprazole from another second-generation antipsychotic: a retrospective chart review. J Clin Psychiatry 2007; 68: 06-09.
17. Svestka J, Bitter I. Nonadherence to antipsychotic treatment in patients with schizophrenic disorders. Neuroendocrinol Lett 2007; 28 (Suppl 1): 95-116.
18. Weiden PJ, Mackell JA, McDonell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004; 66: 51-57.
19. Ziegenbein M, Wittmann G, Kropp S. Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation. Clin Drug Investig 2006; 26: 117-124.